Compound News and Research

RSS

Prestige Brands second fiscal quarter net revenue decreases 3% to $78.3 million

Prestige Brands Holdings, Inc. today announced results for the second quarter and first half of fiscal year 2011, which ended on September 30, 2010. The Company also announced the completion on November 1, 2010 of the acquisition of Blacksmith Brands, Inc., which added five over-the-counter healthcare products to its business.

4 Nov 2010

Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

Researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco, and Pfizer Inc., have determined that two new compounds may be effective in treating both alcohol and nicotine dependence at the same time.

4 Nov 2010

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

USPTO reconfirms Hovione's patent claims to flumethasone, reverses rejection

Hovione and Dickstein Shapiro LLP are pleased to announce that the U.S. Patent and Trademark's Board of Patent Appeals and Interferences has reconfirmed Hovione's patent claims to a method of making flumethasone and its 17-carboxyl androsten analogue, two key intermediates on the synthesis of fluticasone, an important corticosteroid used in asthma medications, reversing a rejection by the reexamination examiner.

4 Nov 2010

Aestus receives $244,000 grant from QTDP program

Today Aestus Therapeutics, Inc. announced that it has been awarded a $244,000 grant from the U.S. Government's Qualifying Therapeutic Discovery Project program.

4 Nov 2010

New noninvasive technique to detect methemoglobin level

Potentially harmful levels of methemoglobin which can build up in patients receiving certain anesthetics are detectable using a new, noninvasive monitoring technique called pulse CO-oximetry, reports a study in the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

4 Nov 2010

Modified sugar compound protects against world's deadliest viruses

When a team of European researchers sought to discover how a class of antiviral drugs worked, they looked in an unlikely place: the sugar dish. A new research report appearing in the Journal of Leukocyte Biology suggests that a purified and modified form of a simple sugar chain may stop fast-acting and deadly viruses, such as Ebola, Lassa, or Marburg viruses, in their tracks.

4 Nov 2010

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae.

4 Nov 2010

Aeolus receives $489,000 grant under QTDP program for two lead compounds

Aeolus Pharmaceuticals, Inc. today announced that it has been awarded a total of approximately $489,000 under the Qualifying Therapeutic Discovery Grant Program (QDTP) administered by the Internal Revenue Service and the Department of Health and Human Services.

4 Nov 2010

Bristol-Myers Squibb and Simcere partner to co-develop oncology compound

Bristol-Myers Squibb Company and Simcere Pharmaceutical Group, a leading pharmaceutical company in China, today announced an innovative strategic partnership to co-develop BMS-817378, a preclinical small molecule MET/VEGFR-2 inhibitor.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA (methylphenidate HCl extended-release tablets).

3 Nov 2010

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV). These new data were presented today at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) international meeting in Boston, Massachusetts.

3 Nov 2010

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

ImmunoGen, Inc. a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that several ImmunoGen poster presentations will be made at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held in Berlin, Germany, November 16-19, 2010.

3 Nov 2010

Nile announces results of CD-NP Phase 2 study in renally compromised ADHF patients

Nile Therapeutics, Inc. a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced results of its Phase 2 study evaluating its lead compound CD-NP in patients with acute decompensated heart failure (ADHF) and mild to moderate renal insufficiency. Study results demonstrated that multiple doses were characterized as well tolerated with favorable drug activity in this acute patient population.

3 Nov 2010

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has been notified that it has been awarded approximately $489,000 total in two federal grants under the Qualifying Therapeutic Discovery Project ("QTDP") Program.

2 Nov 2010

Effective treatment for brain cancer in daffodils

When looking for new ways to treat aggressive brain cancers, an international team of scientists turned a new leaf and "discovered" the lowly daffodil. A new research study published in the November 2010 print issue of The FASEB Journal (http://www.fasebj.org) offers hope that a natural compound found in daffodil bulbs, called narciclasine, may be a powerful therapeutic against biologically aggressive forms of human brain cancers.

2 Nov 2010

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Valeant Pharmaceuticals International, Inc. and Kadmon Pharmaceuticals LLC have concluded two strategic agreements for the development and commercialization of taribavirin and the commercial marketing of ribavirin in the treatment of viral diseases, including hepatitis C virus (HCV).

1 Nov 2010

Compound News and Research

Prestige Brands second fiscal quarter net revenue decreases 3% to $78.3 million

Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

USPTO reconfirms Hovione's patent claims to flumethasone, reverses rejection

Aestus receives $244,000 grant from QTDP program

New noninvasive technique to detect methemoglobin level

Modified sugar compound protects against world's deadliest viruses

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

Aeolus receives $489,000 grant under QTDP program for two lead compounds

Bristol-Myers Squibb and Simcere partner to co-develop oncology compound

PolyMedix receives $488,958 grants under QTDP program

Top 10 Medical Innovations for 2011

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

Nile announces results of CD-NP Phase 2 study in renally compromised ADHF patients

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Effective treatment for brain cancer in daffodils

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News